Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

Financial health

Karyopharm Therapeutics Inc. financial health

Start with the overall verdict and the rule-based risk checks for KPTI, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Stretched

Leverage or liquidity signals may be adding financial risk.

Debt exceeds cash and investments Healthy short-term liquidity Negative equity

Cash & Investments

$91.17M

Debt Cushion

-$139.71M

Current Ratio

1.1x

Interest Coverage

Not available

Risk checks

7 of 9 checks flagged

  • Positive equity

    Negative

    Passes when: Shareholders’ equity is above zero.

  • Interest coverage

    -1.8×

    Passes when: Operating income is at least 1.5 times interest expense.

  • Manageable net debt

    Negative EBITDA

    Passes when: Net debt is below 3 times EBITDA.

  • Debt repayment from cash flow

    Negative FCF

    Passes when: Free cash flow could repay all debt within 5 years.

  • Altman Z-score trend

    -14.22 → -23.89

    Passes when: The Z-score is stable or rising, or stays above 2.99.

  • Debt growth versus revenue growth

    9.3% vs. -2.4%

    Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.

  • Share dilution

    +17.9% per year

    Passes when: Diluted share count grows no more than 2% per year.

  • Short-term liquidity

    1.1×

    Passes when: Current assets are at least 1 times current liabilities.

  • Near-term debt coverage

    2.8×

    Passes when: Cash and short-term investments cover debt due within 12 months.

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

No financial scores available.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$90.85M

Q1 2026

3Y +32.9%1Y +50.1%

Quick Ratio

1.0x

Q1 2026

Current Ratio

1.1x

Q1 2026

Cash Ratio

0.8x

Q1 2026

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Working capital (Q1 2026)

$9.03M

Current assets − current liabilities

Days sales outstanding

65 d

-12 days vs. prior year

Days inventory outstanding

248 d

-40 days vs. prior year

Days payables outstanding

246 d

-65 days vs. prior year

Cash conversion cycle

68 d

+13 days vs. prior year

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$230.87M

Q1 2026

3Y +6.6%1Y -1.2%

Debt/Equity

-0.9x

Q1 2026

Debt/Assets

1.8x

Q1 2026

Interest Coverage

—

Q1 2026

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Net debt

$140.02M

Total debt − cash − short-term investments

Net debt / EBITDA

Negative EBITDA

Above 3× is elevated

Free cash flow / debt

-25.6%

Share of debt one year of FCF could repay

Years to repay debt

Negative FCF

Total debt ÷ free cash flow

Operating cash flow / current liabilities

-0.5×

Above 1× funds a year of obligations

Interest coverage

-1.8×

Operating income ÷ interest expense

Debt maturity

Cash and short-term investments cover short-term debt 2.8×.

Due within 12 months$32.23MDue later$192.16M

Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$317,000.00

Q1 2026

1Y -9.7%

Assets

$131.42M

Q1 2026

3Y +7.8%1Y +21.2%

Liabilities

$397.06M

Q1 2026

3Y +4.9%1Y -1.1%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q1 2026).

$397.06M in liabilities against $131.42M in assets

  • Payables1.1%
  • Short-term debt8.1%
  • Long-term debt48.4%
  • Deferred revenue18.2%
  • Other liabilities24.2%

Shareholders' equity is negative (-$265.65M), so liabilities exceed total assets. Buybacks funded with debt are a common cause; check whether cash flow supports the debt.

Goodwill + intangibles

$0

0.0% of total assets

Share of equity

Negative equity

Above 50% leaves little tangible backing

Tangible equity

-$265.65M

Equity left after writing off goodwill and intangibles

Deferred revenue

$72.34M

Customer prepayments: a liability settled by delivering service, not cash

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

+17.9%

Compound annual rate from FY 2020 to FY 2025

Stock-based compensation

$13.5M

Dividends paid

None

TTM to Q1 2026

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

None

TTM to Q1 2026

Weighted diluted shares outstanding

Competitor health

How does Karyopharm Therapeutics Inc. compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

X4 Pharmaceuticals, Inc.

XFOR:NASDAQ

$360.30M0.410.272.03—9.9810.168.43

INmune Bio, Inc.

INMB:NASDAQ

$50.51M0.040.030.52—3.553.552.94

Telomir Pharmaceuticals, Inc. Common Stock

TELO:NASDAQ

$38.16M0.080.060.65—5.145.145.10

Questions

Financial health questions

Common questions about KPTI's balance sheet, answered from the reported figures.

Is KPTI's balance sheet healthy?

Karyopharm Therapeutics Inc. (KPTI) has a current ratio of 1.08, a quick read on short-term liquidity.

How leveraged is KPTI?

Debt to equity is -0.87, which helps judge how much financing risk sits on the balance sheet.